Eli Lilly (NYSE: LLY) just dropped a bomb on the market with their Phase 3b TOGETHER-PsO trial results released February 18, 2026. The combination of Taltz (ixekizumab) and Zepbound (tirzepatide) demonstrated superior efficacy in treating adults suffering from moderate-to-severe plaque psoriasis alongside obesity. You heard that right—two therapies synergizing to tackle both skin issues and weight problems at once is something traders didn’t see coming. With about 61% of psoriasis patients also dealing with obesity or overweight conditions, this is a pivotal move for both patients and investors alike.
The TOGETHER-PsO study met its primary endpoint, showing a staggering 27.1% of participants achieving complete skin clearance (PASI 100) along with ?10% weight loss after 36 weeks—a stark contrast to just 5.8% in the Taltz monotherapy group. Numbers like these aren't just numbers; they represent lives changed, which means this could be big for Lilly’s bottom line if they play their cards right.
Taltz vs Monotherapy: What the Data Reveals
The trial findings are as compelling as they are transformative. The secondary endpoint revealed that patients on the combined therapy were a whopping 40% more likely to achieve PASI 100 compared to those on Taltz alone (40.6% vs. 29%). This kind of data points toward an unprecedented dual-action treatment model that effectively reduces disease burden.
“Psoriasis and obesity can profoundly impact how people feel... These PASI 100 results represent far more than a clinical milestone.” - Adrienne Brown, Lilly Immunology President
This isn’t just another drug combination hitting the market; it's significant enough to rewrite treatment protocols moving forward. As doctors become aware of these results, expect them to pivot quickly towards comprehensive treatment options instead of treating each condition separately.
